



Correction to: Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU

Sohita Dhillon¹

Published online: 21 March 2019
© Springer Nature 2019

Correction to:

Clinical Drug Investigation (2019) 39:221–229
<https://doi.org/10.1007/s40261-018-0741-2>

The article Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU, written by Sohita Dhillon, was originally published Online First without open access. After publication in volume 39, issue 2, page 221–229 Puma Biotechnology, Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Puma Biotechnology, Inc. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial

use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40261-018-0741-2>.

✉ Sohita Dhillon
demail@springer.com

¹ Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand